NASDAQ:CEMI Chembio Diagnostics (CEMI) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.45▼$0.4650-Day Range$0.33▼$0.4652-Week Range$0.19▼$1.24Volume351,600 shsAverage Volume661,416 shsMarket Capitalization$16.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Chembio Diagnostics (NASDAQ:CEMI) StockChembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.Read More Receive CEMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address CEMI Stock News HeadlinesMay 25, 2023 | americanbankingnews.comChembio Diagnostics (NASDAQ:CEMI) Now Covered by Analysts at StockNews.comMay 17, 2023 | americanbankingnews.comChembio Diagnostics (NASDAQ:CEMI) Receives New Coverage from Analysts at StockNews.comJune 1, 2023 | UNKNOWN (Ad)Lithium Has Boomed And This American Stock Is Ready..Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!May 1, 2023 | americanbankingnews.comChembio Diagnostics (NASDAQ:CEMI) Coverage Initiated by Analysts at StockNews.comApril 28, 2023 | americanbankingnews.comChembio Diagnostics, Inc. (NASDAQ:CEMI) Major Shareholder Credit Advisors Ll Perceptive Buys 39,506 SharesApril 28, 2023 | americanbankingnews.comInsider Buying: Chembio Diagnostics, Inc. (NASDAQ:CEMI) Major Shareholder Buys $31,590.00 in StockApril 27, 2023 | finance.yahoo.comBiosynex Completes Acquisition of Chembio Diagnostics, Inc.April 27, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Arbutus Biopharma (ABUS) and Chembio Diagnostics (CEMI)June 1, 2023 | UNKNOWN (Ad)Lithium Has Boomed And This American Stock Is Ready..Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!April 25, 2023 | americanbankingnews.comChembio Diagnostics (NASDAQ:CEMI) Research Coverage Started at StockNews.comApril 24, 2023 | americanbankingnews.comChembio Diagnostics (NASDAQ:CEMI) Coverage Initiated at StockNews.comApril 21, 2023 | americanbankingnews.comInsider Buying: Chembio Diagnostics, Inc. (NASDAQ:CEMI) Major Shareholder Acquires 137,000 Shares of StockApril 20, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with BiosynexApril 19, 2023 | finance.yahoo.comChembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023April 19, 2023 | americanbankingnews.comCredit Advisors Ll Perceptive Purchases 140,134 Shares of Chembio Diagnostics, Inc. (NASDAQ:CEMI) StockApril 14, 2023 | msn.comChembio Diagnostics And 2 Other Stocks Under $1 Insiders Are Aggressively BuyingApril 14, 2023 | americanbankingnews.comChembio Diagnostics, Inc. (NASDAQ:CEMI) Major Shareholder Credit Advisors Ll Perceptive Buys 129,000 SharesApril 10, 2023 | finance.yahoo.comChembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023April 3, 2023 | finance.yahoo.comChembio’s CEO Letter to StockholdersMarch 28, 2023 | americanbankingnews.comChembio Diagnostics, Inc. (NASDAQ:CEMI) Sees Significant Decrease in Short InterestMarch 21, 2023 | finance.yahoo.comChembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023March 15, 2023 | finance.yahoo.comBiosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.March 15, 2023 | finance.yahoo.comChembio Announces Letter to Stockholders Regarding Tender OfferFebruary 24, 2023 | finance.yahoo.comChembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis SystemFebruary 8, 2023 | benzinga.comMoore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law FirmFebruary 2, 2023 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chembio Diagnostics, Inc. BuyoutFebruary 1, 2023 | finance.yahoo.comFrench Rapid Testing Company Scoops Up Chembio Diagnostics For $17MSee More Headlines Receive CEMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address CEMI Company Calendar Last Earnings11/04/2021Today5/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CEMI CUSIPN/A CIK1092662 Webwww.chembio.com Phone(631) 924-1135Fax631-924-2065Employees337Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,290,000.00 Net Margins-47.03% Pretax Margin-46.96% Return on Equity-113.57% Return on Assets-38.22% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.04 Sales & Book Value Annual Sales$48.34 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book0.95Miscellaneous Outstanding Shares36,726,000Free Float35,514,000Market Cap$16.71 million OptionableNot Optionable Beta1.85 Key ExecutivesRichard L. EberlyPresident, Chief Executive Officer & DirectorPaul J. AngelicoChief Operations Officer & Executive VPLawrence J. SteenvoordenChief Financial Officer, Secretary & Executive VPJavan EsfandiariExecutive VP, Chief Science & Technology OfficerAtif RizviVice President-FinanceKey CompetitorsNeuroSense TherapeuticsNASDAQ:NRSNZynerba PharmaceuticalsNASDAQ:ZYNETFF PharmaceuticalsNASDAQ:TFFPEvelo BiosciencesNASDAQ:EVLOTonix PharmaceuticalsNASDAQ:TNXPView All CompetitorsInsiders & InstitutionsHRT Financial LPBought 96,434 shares on 5/12/2023Ownership: 0.263%Virtu Financial LLCBought 62,646 shares on 5/1/2023Ownership: 0.390%Simplex Trading LLCSold 15,700 shares on 4/27/2023Ownership: 0.000%Credit Advisors Ll PerceptiveBought 39,506 shares on 4/24/2023Total: $17,777.70 ($0.45/share)Credit Advisors Ll PerceptiveBought 70,200 shares on 4/21/2023Total: $31,590.00 ($0.45/share)View All Insider TransactionsView All Institutional Transactions CEMI Stock - Frequently Asked Questions How were Chembio Diagnostics' earnings last quarter? Chembio Diagnostics, Inc. (NASDAQ:CEMI) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.05. The firm earned $12.06 million during the quarter. Chembio Diagnostics had a negative net margin of 47.03% and a negative trailing twelve-month return on equity of 113.57%. During the same period in the prior year, the firm earned ($0.28) EPS. What other stocks do shareholders of Chembio Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and ReWalk Robotics (RWLK). What is Chembio Diagnostics' stock symbol? Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI." Who are Chembio Diagnostics' major shareholders? Chembio Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.39%), HRT Financial LP (0.26%) and Simplex Trading LLC (0.00%). View institutional ownership trends. What is Chembio Diagnostics' stock price today? One share of CEMI stock can currently be purchased for approximately $0.46. How much money does Chembio Diagnostics make? Chembio Diagnostics (NASDAQ:CEMI) has a market capitalization of $16.71 million and generates $48.34 million in revenue each year. The company earns $-23,290,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. How many employees does Chembio Diagnostics have? The company employs 337 workers across the globe. How can I contact Chembio Diagnostics? Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The official website for the company is www.chembio.com. The company can be reached via phone at (631) 924-1135, via email at investor@chembio.com, or via fax at 631-924-2065. This page (NASDAQ:CEMI) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chembio Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.